Baidu
map

Nucleic Acid Research发布第一个人类自身抗原数据库

2016-10-22 佚名 生物谷

自身抗体是一类由B细胞免疫系统分泌,可识别自身蛋白(自身抗原)的抗体分子。它对于维持生物体自身平衡、区分正常与异常增殖细胞以及免疫系统紊乱中均扮演着关键的角色。鉴于其重要的生理功能,发现这些自身抗体的靶标抗原并阐明它们在临床肿瘤和自身免疫病诊断和治疗中的价值则显示出重要的科学意义。例如,2012年美国FDA批准了一组由七个肿瘤自身抗原(p53、NY-ESO-1、 CAGE、GBU4-5、Ann

自身抗体是一类由B细胞免疫系统分泌,可识别自身蛋白(自身抗原)的抗体分子。它对于维持生物体自身平衡、区分正常与异常增殖细胞以及免疫系统紊乱中均扮演着关键的角色。鉴于其重要的生理功能,发现这些自身抗体的靶标抗原并阐明它们在临床肿瘤和自身免疫病诊断和治疗中的价值则显示出重要的科学意义。例如,2012年美国FDA批准了一组由七个肿瘤自身抗原(p53、NY-ESO-1、 CAGE、GBU4-5、Annexin1和SOX2)组成的特征性图谱,Early CDT?-Lung test,用于肺癌的早期筛查

自1945年第一个人类自身抗原以来,国际上对自身抗体及其靶标抗原开展了大量的基础和应用研究,发表文章12万余篇。然而迄今为止却尚未有工作系统的汇总和归纳这一类特殊的蛋白分子。为了填补这一国际空白,国家蛋白质科学中心(北京)于晓波课题组联合李栋、Henning课题组,采用大量文献挖掘方法从PubMed数据库中提取45 830自身抗原摘要和94 313句子,然后采用bio-entity recognizer程序缩小到25 520 摘要, 43 253 句子和 3984 自身抗原候选分子。最后由具有丰富研究经验的专家进行五轮严格的人工核对,最终确定了1126自身抗原基因,涵盖了肿瘤、心血管疾病和自身免疫病等1071种人类相关疾病,构建了第一个全面的人类自身抗原数据库(AAgAtlas1.0)(http://biokb.ncpsb.org/aagatlas/)。对肝癌相关自身抗原开展初步生物信息学分析发现这些抗原基因参与了细胞周期、细胞凋亡、基因表达和免疫系统等多个重要的生物学过程,表明了这些蛋白在肝癌发生发展中可能具有扮演重要的角色。该数据库对于理解人类自身抗原以及开展基础和转化医学研究具有重要的应用价值。该工作发表在2017年Nucleic Acid Res期刊的数据库专刊上。国家蛋白质科学中心(北京)博士生王聃为该文章的第一作者,于晓波、李栋和Henning Hermjakob教授为共同通讯作者。

国家蛋白质科学中心(北京),又称凤凰中心,是国家发展改革委员会批准立项的国家重大科技基础设施之一。拥有高通量、高精度的蛋白质组研究平台、蛋白质功能分析平台、生物信息学平台、转化医学平台以及实验动物中心、生物样本库等完善的蛋白质研究体系,主要开展蛋白质组学、代谢组学、蛋白质功能等创新研究。其研究成果将广泛应用和服务于疾病诊断标志物、新药创制、传染病防治、农作物改良、生物能源转化等多个领域发展。

于晓波 国家蛋白质科学中心(北京)副研究员,2015年9月入选"凤凰工程"全球海外人才招聘计划回国工作,为国家蛋白质科学中心(北京)蛋白质组学新技术研究室负责人;研究方向是高通量蛋白质组学分析新技术、蛋白质和抗体图谱与疾病的相关性、疾病相关蛋白质分子的发现与研究。

李栋 国家蛋白质科学中心(北京)研究员,博士生导师。北京市优秀青年人才,总后勤部优秀青年科技人才扶持对象,Proteomics编委。主要从事蛋白质组生物信息学研究。

Henning Hermjakob国家蛋白质科学中心(北京)研究员,领导欧洲生物信息所(EMBL-EBI)的分子系统小组,通过研究分子间相互作用(IntAct),规划途径(Reactome)到高水平系统生物学模型(BioModels)的蛋白质可视化。HUPO的创建成员和联合主席,英国蛋白质研究组执行委员会成员,以及蛋白质学资深编辑,Henning Hermjakob致力于蛋白质学和系统生物学的标准化表达。

参考文献:

Dan Wang, Liuhui Yang, Ping Zhang, Joshua LaBaer, Henning Hermjakob*, Dong Li* and Xiaobo Yu*. AAgAtlas 1.0: a human autoantigen database. Nucl. Acids Res. first published online October 19, 2016. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1991574, encodeId=b90c19915e499, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 15 11:13:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911415, encodeId=afc11911415d8, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Feb 05 14:13:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810835, encodeId=f1c1181083582, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 28 22:13:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557749, encodeId=cf7b155e74985, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623228, encodeId=8d481623228af, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2017-01-15 xlxchina
  2. [GetPortalCommentsPageByObjectIdResponse(id=1991574, encodeId=b90c19915e499, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 15 11:13:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911415, encodeId=afc11911415d8, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Feb 05 14:13:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810835, encodeId=f1c1181083582, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 28 22:13:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557749, encodeId=cf7b155e74985, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623228, encodeId=8d481623228af, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2017-02-05 wodejia-dayu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1991574, encodeId=b90c19915e499, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 15 11:13:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911415, encodeId=afc11911415d8, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Feb 05 14:13:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810835, encodeId=f1c1181083582, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 28 22:13:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557749, encodeId=cf7b155e74985, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623228, encodeId=8d481623228af, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1991574, encodeId=b90c19915e499, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 15 11:13:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911415, encodeId=afc11911415d8, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Feb 05 14:13:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810835, encodeId=f1c1181083582, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 28 22:13:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557749, encodeId=cf7b155e74985, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623228, encodeId=8d481623228af, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-24 yangshch
  5. [GetPortalCommentsPageByObjectIdResponse(id=1991574, encodeId=b90c19915e499, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jan 15 11:13:00 CST 2017, time=2017-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911415, encodeId=afc11911415d8, content=<a href='/topic/show?id=dbda185590' target=_blank style='color:#2F92EE;'>#acid#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1855, encryptionId=dbda185590, topicName=acid)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ca4300, createdName=wodejia-dayu, createdTime=Sun Feb 05 14:13:00 CST 2017, time=2017-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1810835, encodeId=f1c1181083582, content=<a href='/topic/show?id=5af886363e5' target=_blank style='color:#2F92EE;'>#自身抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86363, encryptionId=5af886363e5, topicName=自身抗原)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Tue Feb 28 22:13:00 CST 2017, time=2017-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557749, encodeId=cf7b155e74985, content=<a href='/topic/show?id=d2601533982' target=_blank style='color:#2F92EE;'>#Research#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15339, encryptionId=d2601533982, topicName=Research)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96ab14929432, createdName=yangshch, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623228, encodeId=8d481623228af, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Mon Oct 24 08:13:00 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map